All In Biotech

Drug Trial Radar · NCT05222932

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and IL-2 Coding Oncolytic Adenovirus TILT-123 and Avelumab in Solid Tumor Patients (Melanoma and SCCHN) Refractory to or Progressing After Anti-PD(L)1

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Mar 8, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
TILT Biotherapeutics Ltd.Industry
Sponsor type
Industry
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.

Conditions

  • Melanoma
  • Head and Neck Squamous Cell Carcinoma

Interventions

  • TILT-123Biological

    TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

  • AvelumabDrug

    Anti-PDL1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with any (serious and non-serious) Adverse Events.Time frame: 85 days
  2. Number of Participants with abnormal laboratory values.Time frame: 85 days
  3. Number of Participants with vital sign abnormalities.Time frame: 85 days
  4. Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)Time frame: 85 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Docrates Cancer Center

    Helsinki, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.